The effect of docetaxel on the survival and clonogenic activity of MCF-7 mammospheres culture enriched with cancer stem cells


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Introduction. Cancer stem cells (CSCs), which are less sensitive to chemotherapeutic drugs than other tumor cells, play a key role in the initiation and development of the tumor process. Maintenance of CSCs determines the risk of cancer recurrence. The aim of the study. To study the effect of docetaxel on CSCs survival and self-renewal in the human mammary adenocarcinoma MCF-7 cells cultured as mammospheres. Methods. The effect of docetaxel on the CSCs survival was studied after 72 and 120 h of cultivation with the drug at concentrations of 0, 1, 10 and 100 nmol/l. For this purpose, the total number of living cells was counted, the fraction of CSCs with CD44+/CD24-/low phenotype was determined using flow cytometry, and the absolute number of CSCs was calculated in each sample. The effect of docetaxel on the CSCs repopulation was determined by counting mammospheres formed 7 days after cells were washed from docetaxel after 120 h cultivation with the drug at concentrations 0, 1, 10 and 100 nmol/l. Results. The cultivation of mammospheres with docetaxel for 72 h resulted in an insignificant decrease in both of the total cell number and the CSCs fraction. At the same time, there was a significant decrease in the number of CSCs. The cultivation of mammospheres at all studied docetaxel concentrations for 120 hours resulted in a significant decrease in the total number of cells, the proportion and the number of CSCs and their clonogenic activity that represents the ability of the CSC to repopulate. Conclusion. CSCs of MCF-7 mammospheres were shown to be highly sensitive to docetaxel after prolonged cultivation (120 h). Docetaxel inhibited the ability of CSCs to self-renewal, which plays a crucial role in the tumor and metastasis initiation

Full Text

Restricted Access

About the authors

V. G Shuvatova

National Research Center «Kurchatov Institute»

Email: Shuvatova VG@nrcki.ru

Yu. P Semochkina

National Research Center «Kurchatov Institute»

G. A Posypanova

National Research Center «Kurchatov Institute»

E. Yu Moskaleva

National Research Center «Kurchatov Institute»

References

  1. Li F., Tiede B., Massague J. et al. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Research. 2007; 17 (1): 3-14. https://doi.org/10.1038/sj.cr.7310118.
  2. Zhao J. Cancer stem cells and chemore-sistance: The smartest survives the raid. Pharmacol Ther. 2016; 160: 145-58. https:// doi.org/10.1016/j.pharmthera.2016.02.008.
  3. Chuthapisith S., Eremin J., El-Sheemey M., Eremin O. Breast cancer chemoresistance: emerging importance of cancer stem cells. Surg Oncol. 2010; 19 (1): 27-32. https://doi.org/10.1016/j.suronc.2009.01.004.
  4. Krause M., Yaromina A., Eicheler W, Koch U, Baumann M. Cancer Stem Cells: Targets and Potential Biomarkers for Radiotherapy Clin. Cancer Res. 2011; 17 (23): 7224-9. https://doi.org/10.1158/1078-0432.CCR-10-2639.
  5. Tsou S.-H., Chen T.-M., Hsiao H.-T., Chen Y.-H. A Critical Dose of Doxorubicin Is Required to Alter the Gene Expression Profiles in MCF-7 Cells Acquiring Multidrug Resistance. PLoS One. 2015; 10 (1): e0116747. https://doi.org/10.1371/journal. pone.0116747.
  6. Bao B., Ahmad A., Azmi A.S., Ali S., Sarkar F.H. Cancer Stem Cells (CSCs) and Mechanisms of Their Regulation: Implications for Cancer Therapy. Curr Protoc Pharmacol. 2013; Chapter 14: Unit 14.25. https://doi. org/10.1002/0471141755.ph1425s61.
  7. Tanaka H., Nakamura M., Kameda C. The Hedgehog Signaling Pathway Plays an Essential Role in Maintaining the CD44+CD24-/low Subpopulation and the Side Population of Breast Cancer Cells, Anticancer Research. 2009; 29 (6): 2147-57.
  8. Ray A., Vasudevan S., Sengupta S. 6-Shogaol Inhibits Breast Cancer Cells and Stem Cell-Like Spheroids by Modulation of Notch SignalingPathway and Induction of Autophagic Cell Death. PLoS ONE. 2015; 10 (9): e0137614. https://doi.org/10.1371/ journal.pone.0137614
  9. Hernandez-Vargas H., Palacios J., Moreno-Bueno G. Telling cells how to die: docetaxel therapy in cancer cell lines. Cell cycle. 2007; 6 (7): 780-3
  10. Zasadil L.M., Andersen K.A., Yeum D., Rocque G.B., Wilke L.G., Tevaarwerk A.J., Raines R.T., Burkard M.E., Weaver B.A. Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindles. Sci Transl Med. 2014; 6 (299) 229ra243. https://doi.org/10.1126/ scitranslmed.3007965
  11. Wu X., Sooman L., Lennartsson J., Bergstrom S., Bergqvist M., Gullbo J., Ekman S. Microtubule inhibition causes epidermal growth factor receptor inactivation in oesophageal cancer cells. Intern. J. Oncol. 2012; 42 (1): 297-304. https://doi.org/10.3892/ ijo.2012.1710
  12. Dontu G., Abdallah W.M., Foley J.M., Jackson K.W., Clarke M.F., Kawamura M.J., Wicha M.S. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003; 17 (10): 1253-70.
  13. Wang R., Lv Q., Meng W., Tan Q., Zhang S., Mo X., Yang X. Comparison of mammosphere formation from breast cancer cell lines and primary breast tumors. J. Thorac Dis. 2014; 6 (6): 829-37. https://doi. org/10.3978/j.issn.2072-1439.2014.03.38.
  14. Baker S.D., zhao M., Lee C.K.K., Verweij J., Zabelina Y, Brahmer J.R., Wolff A.C., Sparreboom A., Carducci M.A. Comparative Pharmacokinetics of Weekly and Every-Three-Weeks Docetaxel. Clin. Cancer Res. 2004; 10: 1976-83.
  15. Brunsvig P.F., Andersen A., Aamdal S., Kristensen V., Olsen H. Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy BMC Cancer. 2007; 23 (7): 197. https://doi. org/10.1186/1471-2407-7-197.
  16. Mori T., Kinoshita Y, Watanabe A., Yamaguchi T., Hosokawa K., Honjo H. Retention of paclitaxel in cancer cells for 1 week in vivo and in vitro. Cancer Chemother Pharmacol. 2006; 58 (5): 665-72.
  17. Crabtree J.S., Miele L. Breast Cancer Stem Cells. Biomedicines 2018; 6: 77. https://doi. org/10.3390/biomedicines6030077.
  18. Rivas S., Gomez-Oro C., Anton I.M., Wandosell F. Role of Akt Isoforms Controlling Cancer Stem Cell Survival, Phenotype and Self-Renewal Biomedicines. 2018; 6 (1). pii: E29. https://doi.org/10.3390/biomedi-cines6010029.
  19. Zhang X., Shao J., Li X., Cui L., Tan Z. Docetaxel promotes cell apoptosis and decreases SOX2 expression in CD133-expressing hepatocellular carcinoma stem cells by suppressing the PI3K/AKT signaling pathway Oncol Rep. 2019; 41 (2): 1067-74. https://doi.org/10.3892/or.2018.6891.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies